| Document |
Document Title |
|
JP2012051935A |
To provide new steroids which possess antiprogestational activity with minimal antiglucocorticoid activity.In addition to providing compounds of formula I, the present invention relates to methods where the compounds of Formula I are adv...
|
|
JP4869594B2 |
The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, ...
|
|
JP4837912B2 |
The present invention relates to the use of xanthan gum as re-epithelializing agent and, in particular, to a pharmaceutical formulation comprising xanthan gum as a re-epithelializing active principle. Said use and composition speed up an...
|
|
JP4796693B2 |
The present invention provides in one aspect, a novel method for recovering an organic solute from a predominantly aqueous solution. In one embodiment, the solution is contacted with a dry, non-conditioned sorbent medium held by a suppor...
|
|
JP2011178777A |
To provide an outstanding melanocyte proliferation inhibitor and to provide an outstanding pharmaceutical composition for pigmentation inhibiting.A melanocyte proliferation inhibitor containing hydrocortisone is disclosed. A melanin prod...
|
|
JP4749550B2 |
Androgenic steroids having a (14beta,17alpha-)-17-(hydroxymetheyl) configuration, useful for the preparation of male contraceptives and pharmaceutical formulations for the treatment of androgen insufficiency.
|
|
JP2011148821A |
To provide a novel method for preparing a cortisol conjugate.The method for preparing the cortisol conjugate includes reacting 3-cortisolcarboxymethyl oxime conjugated to bovine serum albumin (3-CMO-BSA) with sodium borohydride.
|
|
JP4718445B2 |
The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflamm...
|
|
JP4719144B2 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide ...
|
|
JP4712689B2 |
A process for the sterilization of water insoluble solid medicinal substances is described. The process provides the sterilization of drug substances, which are suitable for pulmonary administration. In particular, the process is used in...
|
|
JP4698773B2 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
JP4674286B2 |
To obtain an emulsifying agent which has excellently emulsifying action and is highly safe to organisms due to low toxicity and low skin irritation, or the like, has excellent adhesivity to the skin and sense of use and is especially sui...
|
|
JP2011507878A |
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: wherein L, R1, R2, R3, R4, R5, and R6 are...
|
|
JP4606408B2 |
The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory dise...
|
|
JP4598268B2 |
The invention provides sterile glucocorticosteroids and sterile formulations containing glucocorticosteroid and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or the lungs.
|
|
JPWO2009022477A1 |
To provide a polymer polymer in which a physiologically active substance is uniformly distributed at a high density. The above problem can be solved by selecting and using polynorbornene as a polymer polymer. [Selection diagram] None
|
|
JP2010531845A |
Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient t...
|
|
JP4553166B2 |
PCT No. PCT/GB96/01054 Sec. 371 Date Mar. 3, 1998 Sec. 102(e) Date Mar. 3, 1998 PCT Filed May 1, 1996 PCT Pub. No. WO96/34858 PCT Pub. Date Nov. 7, 1996Compounds, compositions, and methods of use as a pharmaceutical, where the compounds ...
|
|
JP4541698B2 |
3-Hydroxy-7-hydroxy steroids and 3-oxo-7-hydroxy steroids, especially the 7β-isomers thereof, and pharmaceutically acceptable esters thereof are useful for protection against ischaemia-induced damage to peripheral organs, such as the he...
|
|
JP4541166B2 |
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3 alpha -hydroxy-5-reduced steroid derivatives.
|
|
JP4481831B2 |
An improved stereoselective process for the preparation of 6alpha-fluoropregnane derivatives of formula (I), comprising the reaction of 3-benzoyloxy Delta3,5-pregnane derivatives of formula (II), with an electrophilic fluorination agent ...
|
|
JP2010516686A |
Compositions with improved stability comprising a pharmaceutically acceptable salt of 11-(4-aminophenyl)-19-nofregna-4,9(10)-diene- 3,20-dione derivatives are provided
|
|
JP2010090058A |
To provide a composition for treatment of cancers in which chemotactic capacity of the cancer cell is promoted by steroid preparations and to provide a method for treating cancers by the composition.Cancer is treated by a composition con...
|
|
JP2010070567A |
To provide a method for sterilizing a powdery form glucocorticosteroid, sterile glucocorticosteroid, sterile formulation containing glucocorticosteroid, and use thereof for treating an allergic and/or inflammatory condition of the nose o...
|
|
JP2010059181A |
To provide an improved formulation which, in systems to imitate inhalation, achieves an improved dispersion of the drug.A dry powder composition has a poured bulk density of 0.28-0.38 g/ml and includes one or more potent pharmaceutically...
|
|
JP4417838B2 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
JP2010503722A |
The present invention relates to crystalline ciclesonide methanol solvate Form C, processes for its preparation, its use in the synthesis of crystalline ciclesonide Form A and its use in medicine.
|
|
JP2010013482A |
To provide a medicine for treating multiple myeloma.The medicine for treating multiple myeloma in a patient includes cyclopropane carboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methane sulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-iso-i...
|
|
JP2009545546A |
The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.
|
|
JP4368945B2 |
The invention relates to compounds of the formula : wherein : R1, R2, R3, R4 and R6 each independently represent hydrogen or a (C1-C6)alkyl, R5 is hydrogen, a (C1-C6)alkyl or a group -COR7 where R7 is a (C1-C6)alkyl, n is zero or one, an...
|
|
JP4361976B2 |
The invention relates to a method for the preparation of a mixture of sulfated estrogens containing delta(8,9)-dehydro estrone Ädelta(8,9)DHEÜ or derivatives thereof.
|
|
JP4354809B2 |
The present application provides 17 and/or 21 esters of 17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione having remarkable antiandrogenic activity, methods of using these compounds, and proces...
|
|
JP2009191072A |
To provide a method for treating and preventing certain types of cancers, including primary and metastatic cancers, as well as cancers that are refractory or resistant to conventional chemotherapy.Provided is the method of preventing or ...
|
|
JP2009167188A |
To provide a new compound having a specific strong progesterone-like property and devoid of residual androgenic activity.The compound is expressed by formula (I), wherein R1, R2, R3, R4, R5 and R6 are each a hydrogen atom or a specific s...
|
|
JP2009521511A |
Methods for controlling ocular hypertension by administering anecortave acetate at the site of filtering bleb surgery are disclosed.
|
|
JP4260886B2 |
A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, ...
|
|
JP2009511604A |
Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angio...
|
|
JP4233504B2 |
The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalce...
|
|
JP4213205B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP4170751B2 |
The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchito...
|
|
JP4150846B2 |
|
|
JP4145350B2 |
The invention relates to a 3 alpha -hydroxy, 17-(un)substituted derivatives of the androstane series and 3 alpha -hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at the recently identif...
|
|
JP4095018B2 |
A process for the preparation of high purity flumethasone in high yield involves C3 protecting 9,11beta-epoxy-17alpha,21-dihydroxy-16alpha-methylpregna-1,4
-diene-3,20-dione,21-acetate, fluorinating at 6alpha, removing the C3 protecting ...
|
|
JP2008120839A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
|
JP2008120840A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
|
JP4070463B2 |
A method of producing 3-alkoxy-1,3,5(10)-triene-6-one-steroid derivatives having, in the steroid skeleton thereof, a partial structure of A- and B-rings represented by formula (2) : (wherein R represents an alkyl group, a cycloalkyl grou...
|
|
JP4066272B2 |
Methods, compositions and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
JP2008044957A |
To provide a good antifungal nail varnish composition able to be easily formulated, prepared and preserved.The composition comprises (a) at least one antimycotic agent and (b) at least one film-forming agent wherein the component (b) is ...
|
|
JPWO2005095434A1 |
The present invention is characterized in that a metal selected from an alkali metal and an alkaline earth metal is allowed to act on a pregnane derivative represented by the general formula (I) in the presence of a proton feeder, an ami...
|
|
JPWO2005095432A1 |
The present invention selectively reduces the carbon-carbon double bond of the 5α-pregnane derivative represented by the general formula (II) in the mixture of the 5α-pregnane derivative represented by the general formula (I) and the g...
|
